Top 20 Generic Pharma Companies of 2025 

Note: Columns 1 and 2 represent ranks and companies, while Columns 3, 4, and 5 showcase the total generic revenue of 2023, the total revenue of 2024, and the percentage change. 

20. Alkem 

Generic Segment Revenue: $1.49B 

Founded Year: 1973 

Market Cap: $7.38B 

Total Employees: ~21000 

Headquarters: Maharasthra, India 

Stock Exchange: NSE 

• Alkem Laboratories is a leading Indian pharmaceutical developer with a significant global generics, formulations, and nutraceuticals portfolio; key products include Livoerb, Omee MPS, and Alkem Dexa 

• Reported $1.49B in 2024 generic revenue, a decrease of 1.6% from 2023, attributed to subdued product sales 

• In October 2024, received ANDA approval for Topiramate Oral Solution for epilepsy treatment

19. Glenmark 

Generic Segment Revenue: $1.53B 

Founded Year: 1977 

Market Cap: $6.17B 

Total Employees: 15,800  

Headquarters: Maharasthra, India 

Stock Exchange: NSE 

• Glenmark Pharmaceuticals is an Indian company specializing in branded generics, specialty medicines, and OTC products, with flagship brands such as Glempa, Apremilast, and Sacu VTM 

• Achieved $1.53B in 2024 generic segment revenue, reflecting an 8.9% increase driven by higher sales volumes 

• Launched Lacosamide oral solution (Vimpat) in the U.S. market in December 2024

18. Zydus  

Generic Segment Revenue: $1.57B 

Founded Year: 1952 

Market Cap: $11.21B 

Total Employees: 27,000  

Headquarters: Ahmedabad, India 

Stock Exchange: NSE 

• Zydus is an Indian multinational firm engaged in formulations, APIs, and animal health products; prominent generic offerings include Acamprosate calcium DR tablets and Acetazolamide ER capsules 

• Posted $1.57B in generic revenue for 2024, a 23.1% year-over-year rise due to increased sales activity 

• ZyVac TCV received WHO prequalification, enabling U.N. procurement for typhoid prevention in October 2024

17. Towa Pharmaceutical 

Generic Segment Revenue: $1.6B 

Founded Year: 1951 

Market Cap: $1.01B 

Total Employees: 4,788 

Headquarters: Osaka, Japan 

Stock Exchange:  TYO 

• Towa Pharmaceutical is a Japanese research-based company focused on manufacturing and marketing generic formulations such as Ambroxol and Ropinirole 

• Recorded $1.60B in 2024 generic revenue, representing a 4.1% decline due to market headwinds 

• Towa was granted approval for six generic ingredients and ten new items in August 2024

16. Amneal 

Generic Segment Revenue: $1.68B 

Founded Year: 2002 

Market Cap: $3.25B 

Total Employees: 8,300 

Headquarters: New Jersey, United States 

Stock Exchange: NASDAQ 

• Amneal is an American multinational producing generics, injectables, biosimilars, and specialty drugs, with leading products like Abiraterone Acetate and Chloroquine Phosphate 

• Reported $1.68B in 2024 generic revenues, up 14.5% from the previous year based on robust generic launches 

• Entered into a long-acting injectable development deal with Kashiv in March 2024

15. STADA Arzneimittel 

Generic Segment Revenue: $1.72B 

Founded Year: 1895 

Market Cap: N/A 

Total Employees: 11,500 

Headquarters: Bad Vilbel, Germany 

Stock Exchange: N/A 

• STADA is a German company with portfolios in consumer healthcare, generics, and specialty medicines, including Tilidine, Atorvastatin, and Pantoprazole 

• Saw $1.72B in generic segment revenue in 2024, growing 3.9% year-over-year through product and market expansion 

• Acquired FITO from LEO Pharma in August 2024 to broaden its business

14. KRKA 

Generic Segment Revenue: $1.98B 

Founded Year: 1954 

Market Cap: $7.61B 

Total Employees: 13,000 

Headquarters: Novo Mesto, Slovenia 

Stock Exchange: WSE 

• KRKA is a Slovenian manufacturer offering prescription and non-prescription generics, and animal health products; notable products are Rivaroxia and Zomiren 

• Generated $1.98B in 2024 generic revenue, down 0.2%, reflecting currency-induced declines despite organic growth 

• Formed a joint venture with Laurus Labs in India (January 2024) to expand its regional footprint

13. Gedeon Richter 

Generic Segment Revenue: $2.13B 

Founded Year: 1901 

Market Cap: N/A 

Total Employees: ~10,900 

Headquarters: Budapest, Hungary 

Stock Exchange: FRA 

• Gedeon Richter is a Hungarian pharmaceutical specialist in innovation, generics, and OTCs for women’s health and the central nervous system; key generics include Postinor and Cerazette. 

• Reported a 2024 generic revenue of $2.13B, a 0.5% decrease attributed to weak sales

• Established a collaboration with Bio-Thera for commercializing the Stelara biosimilar (BAT2206) in October 2024

12. Celltrion 

Generic Segment Revenue: $2.41B 

Founded Year: 2002 

Market Cap: $28.65B 

Total Employees: ~2,700 

Headquarters: Incheon, South Korea 

Stock Exchange: KRX 

• Celltrion Healthcare is a South Korean biopharma leader developing generic and biosimilar drugs, with a portfolio featuring Inflectra, Truxima, and Herzuma 

• Achieved $2.41B in generic revenue for 2024, up 43.8% on strong biosimilar sales worldwide 

• In December 2024, Health Canada approved Omlyclo, a Xolair biosimilar, expanding Celltrion’s North American presence

11. Aspen 

Generic Segment Revenue: $2.42B 

Founded Year: 1850 

Market Cap: $2.48B 

Total Employees: ~9,100 

Headquarters:  Durban, South Africa 

Stock Exchange: JSE 

• Aspen is a South African group manufacturing post-patent brands and generics, including sterile injections and APIs, for hospital and consumer segments 

• Delivered $2.42B in generic segment revenue during 2024, up 4.1% year-over-year on organic growth 

• Teamed with PinkDrive in October 2024 to promote cancer screening and awareness

10. Lupin 

Generic Segment Revenue: $2.59B 

Founded Year: 1968 

Market Cap: $9.84B 

Total Employees: ~24,000 

Headquarters: Mumbai, India 

Stock Exchange: NSE 

• Lupin is an Indian multinational developing branded and generic pharmaceuticals, APIs, and biosimilars; key products include Ab-Next, Abdowell, and Adhero

• Registered $2.59B in generic revenue for 2024, an increase of 10.2% driven by U.S. market gains 

• Received tentative U.S. FDA approval for Raltegravir tablets in November 2024

09. Cipla 

Generic Segment Revenue: $3.15B 

Founded Year: 1935 

Market Cap: $13.63B 

Total Employees: ~30,300 

Headquarters: Mumbai, India 

Stock Exchange: NSE 

• Cipla is a global Indian pharmaceuticals giant offering branded medications, generics, and APIs, especially for respiratory and chronic therapies; known for Foracort and Budecort 

• Reported $3.15B in 2024 generic segment revenue, a 5.6% increase attributed to chronic portfolio growth 

• Signed a non-exclusive licensing agreement with Takeda in June 2024 to commercialize Vonoprazan in India

08. Dr. Reddy’s 

Generic Segment Revenue: $3.51B 

Founded Year: 1984 

Market Cap: $11.61B 

Total Employees: ~27,800 

Headquarters: Hyderabad, India 

Stock Exchange: NSE 

• Dr. Reddy’s is an Indian multinational with business lines in global generics and pharmaceutical services; highlights include Lenalidomide, Treprostinil, and Regadenoson generics

• Recorded $3.51B in generic revenue for 2024, a rise of 11.5% on strong international sales 

• Partnered with Senores Pharmaceuticals to launch Ivermectin (Stromectol) in the U.S. in November 2024

07. Teva Pharmaceuticals 

Generic Segment Revenue: $3.59B 

Founded Year: 1944 

Market Cap: $23.26B 

Total Employees: 37,000 

Headquarters: Tel Aviv, Israel 

Stock Exchange: TLV 

• Teva Pharmaceuticals is an Israeli firm specializing in generics, specialty medicines, and biosimilars; portfolio features Acitretin, Acyclovir, and Capecitabine 

• Totaled $3.59B in generic revenue for 2024, up 14.7% year-over-year due to new product launches and high demand 

• Strengthened its oncology biosimilars partnership with mAbxience in October 2024 

06. Aurobindo Pharma 

Generic Segment Revenue: $3.61B 

Founded Year: 1986 

Market Cap: $7.08B 

Total Employees: ~27,700  

Headquarters: Hyderabad, India 

Stock Exchange: NSE 

• Aurobindo Pharma is an India-based global generics and specialty pharma leader, with key generics like Zovirax and Xanax XR 

• Announced $3.61B in 2024 generic revenues, a 10.9% increase, primarily from high demand 

• Subsidiary CuraTeQ Biologics received UK MHRA approval for Bevqolva biosimilar in December 2024

05. Fresenius Kabi 

Generic Segment Revenue: $3.99B 

Founded Year: 1999 

Market Cap: $30.45B 

Total Employees: ~176,200 

Headquarters: Bad Homburg, Germany 

Stock Exchange: ETR 

• Fresenius Kabi is a subsidiary of Germany-based multinational healthcare company Fresenius SE & Co. KGaA. The company develops and distributes essential medicines and technologies for the treatment of chronic conditions 

• Fresenius Kabi’s generic portfolio comprises products such as Adalimumab, Pegfilgrastim, Tocilizumab, and Ustekinumab, among others. Reported 2024 generic segment revenue of $3.99B, a 5.5% decline, mainly due to low biosimilar sales

• Introduced a generic Epinephrine 1mg/1mL in the U.S. in December 2024

04. Viatris 

Generic Segment Revenue: $5.49B 

Founded Year: 2020 

Market Cap: $11.82B 

Total Employees: 32,000 

Headquarters: Pennsylvania, United States 

Stock Exchange: NASDAQ 

• Viatris is an American developer of branded, generics, and complex medicines across multiple therapeutic areas; generics portfolio includes Abiraterone and Acamprosate 

• Reported $5.49B in 2024 generic revenue, a decrease of 1.7% linked to lower international sales 

• Released positive Phase III data for Effexor in Japanese adults with GAD in October 2024

03. Fosun Pharma 

Generic Segment Revenue: $5.6B 

Founded Year: 1978 

Market Cap: $10.69B 

Total Employees: ~40,600 

Headquarters: Shanghai, China 

Stock Exchange: SHA 

• Shanghai Fosun Pharmaceutical (Group), also known as Fosun Pharma, is a Chinese multinational with prescription and generic products, medical devices, and healthcare services; generic offerings include Han Da Yuan and Han Qu You 

• Generated $5.6B in generic revenue for 2024, down 3.7% year-over-year due to moderate sales 

• Gained NMPA approval for Daxxify toxin product in China in September 2024

02. Sun Pharma 

Generic Segment Revenue: $6.26B 

Founded Year: 1983 

Market Cap: $44.28B 

Total Employees: 43,000 

Headquarters: Mumbai, India 

Stock Exchange: NSE 

• Sun Pharma is India’s largest pharmaceutical company, focusing on branded and generic medicines as well as APIs; operates a portfolio including Absenz and Betavert 

• Achieved $6.26B in generic segment revenue, up 7.5%, reflecting robust generic demand in 2024 

• In June 2024, inked a patent-licensing deal with Takeda for the GI drug Voltapraz (Vonoprazan) in India 

01. Sandoz 

Generic Segment Revenue: $10.35B 

Founded Year: 1886 

Market Cap: $26.2B 

Total Employees: 23,000 

Headquarters: Basel, Switzerland 

Stock Exchange: SWX 

• Sandoz is a Swiss industry leader in generics and biosimilars, with a global reach spanning over 100 countries and products like Erelzi and Hyrimoz 

• Generated $10.35B in 2024 generic revenue, a 7.4% increase from 2023 led by global biosimilars expansion 

• Secured European Commission approval for Afqlir (aflibercept), reinforcing its biosimilar leadership. 

Sources:         

• Annual reports       

• SEC Filings       

• Press releases       

• Company websites       

Currency Conversion: Oanda (£1 – $1.25, €1 – $1.04, kr.1 – 0.13, CHF 1 – 1.1, ₩1– 0.00068,  

HUF1 – 0.00253, ZAR1 – 0.0533, ¥1 – 0.13698; Dec 31, 2024)